INTRODUCTION {#sec1-1}
============

*Candida* infections often associated with high morbidity and mortality have increased remarkably during the couple of decades.\[[@ref1]\] The incidence of *Candida* infections is on the rise with the increase in number of immunocompromised patients due to excessive use of immunosuppressive drugs as well as the use of medical and surgical interventions.\[[@ref2]\] Although *Candida albicans* is the most prevalent species,\[[@ref3]\] an epidemiological shift in *Candida* pathogens has been recently noted by the increasing number of infections caused by non*albicans* *Candida* species (NAC).\[[@ref1][@ref3][@ref4][@ref5]\] The increased species diversity and incidence of infections have resulted in the need for an accurate and rapid identification of *Candida* isolates and have become important for proper patient management as various species respond differently to antifungals and for the prevention of emergence of drug resistance.\[[@ref1][@ref2][@ref6]\]

Conventional methods of identification are time-consuming.\[[@ref6][@ref7]\] Commercially available biochemical and molecular methods, which allow identification within several hours, have been developed and evaluated.\[[@ref8]\] The Biomerieux Vitek-2 system includes the Vitek-2 cards that allow species identification by comparison of the biochemical profile with an extensive database. The system also incorporates the antifungal susceptibility testing (AST) cards, which is designed for AST.\[[@ref9]\] Recently, molecular genotyping methods have become more popular for epidemiological analysis.\[[@ref10]\]

AST has been increasingly required in clinical practice. It is already well established that the outcome of invasive fungal infections could be improved by early initiation of appropriate antifungal agent based on the susceptibility profile of infecting *Candida* species.\[[@ref11][@ref12]\] Recently, Biomerieux Vitek-2 expanded its role in this area with a yeast susceptibility test that determines *Candida* growth spectrophotometrically using Vitek-2 microbiology systems, performing fully automated testing of susceptibility to flucytosine, amphotericin B, fluconazole, and voriconazole.\[[@ref12]\]

The earliest possible identification and drug susceptibility profiling of *Candida* infections in immunocompromised patients allow for prompt optimization of antimicrobial therapy and diminished need for additional diagnostic studies, helping timely in saving the life of many patients. Hence, the objectives of this study were to compare the Vitek-2 yeast identification system with conventional and molecular methods of identification and Vitek-2 AST system with the broth microdilution method.

MATERIALS AND METHODS {#sec1-2}
=====================

The study was conducted at the Mycology Laboratory, Department of Microbiology, Maulana Azad Medical College and Associated Lok Nayak Hospitals, New Delhi, India, which is a 1500-bedded tertiary care hospital where patients came from all over the India. All the isolates of *Candida* spp. were recovered from various clinically available specimens, namely, oropharyngeal swab, blood culture, sputum, urine, cerebrospinal fluid, and stool.

The following strains were used as controls for the evaluation of various methods: *C. albicans* ATCC90028, *Candida parapsilosis* ATCC22019, *Candida krusei* ATCC6258, *Candida glabrata* ATCC90030, and *Candida tropicalis* ATCC750.

Identification and speciation of clinical isolates were done by conventional methods, Vitek-2 system, and the molecular methods. For the purpose of comparison, molecular methods were taken as gold standard method.

Identification by conventional methods {#sec2-1}
--------------------------------------

Identification and speciation of *Candida* isolates were done on the basis of germ tube production, morphology on corn meal agar with Tween 80 (Hi Media, India), HiCrome *Candida* agar morphology (Hi Media, India), carbohydrate fermentation, and assimilation tests using yeast nitrogen base agar (Difco, Becton Dickinson, India) as per the standard recommended procedures\[[@ref13][@ref14][@ref15]\] and using the above control strains.

Identification by Vitek-2 system {#sec2-2}
--------------------------------

Pure subcultures suspended in aqueous 0.45% (wt/vol) NaCl to achieve a turbidity equivalent to a McFarland 2.0 standard were measured on the DensiChek turbidity meter (Biomerieux, India), an instrument designed to measure the optical density of an organism suspension. The reading range of the DensiChek turbidity meter is 0.0-4.0 McFarland. The Vitek-2 instrument was automatically filled, sealed, and incubated by individual test cards with prepared culture suspension. Cards were held at 35.5°C for 18 h, with optical density readings taken automatically at every 15 min. Based on these readings, an identification profile was established and interpreted according to a specific algorithm.\[[@ref16]\]

Identification by molecular methods {#sec2-3}
-----------------------------------

Molecular identification was performed by the Southern blot hybridization and random amplified polymorphic DNA (RAPD) analysis. Before genotyping, chromosomal DNA was isolated from each isolate using Xu *et al*. method.\[[@ref17]\] After evaluating the quality of DNA on agarose gel, the DNA concentrations of each sample were measured and were subsequently subjected for further tests as described below:

DNA fingerprinting of the isolates by Southern blot hybridization {#sec2-4}
-----------------------------------------------------------------

For DNA fingerprinting, around 2 μg of chromosomal DNA from each isolate was digested with restriction enzyme EcoR1. Digested DNA was separated on agarose gel (0.8%) in 1XTBE buffer (89 mM Tris borate, 1 mM ethylenediaminetetraacetic acid \[EDTA\]) by applying a voltage gradient of 2 V/cm for 20 h, stained with 0.5 μg/ml, visualized under ultraviolet (UV) light, and photographed. In the next step, separated DNA fragments were denatured *in situ* using alkali and neutralized with acid. The denatured DNA fragments were transferred to nylon membrane by capillary action. Transferred DNA fragments were then cross-linked to the membrane prehybridized in 300 mM phosphate buffer containing 7% sodium dodecyl sulfate (SDS) and 1 mM EDTA at 65°C for 2-4 h. In the next step, immobilized fragment of DNA was hybridized with^32^ *P* labeled *C. albicans*-specific probe CARE-2 at the same temperature for 16 h.\[[@ref18]\] The nylon membrane containing hybridized DNA fragment was washed several times with 2 × SSC containing 0.1% SDS, dried and exposed to X-ray film at −80°C for 16-24 h, and developed.

Random amplified polymorphic DNA {#sec2-5}
--------------------------------

For RAPD analysis, the DNA was purified by the method described by Makimura *et al*.\[[@ref19]\] with slight modifications. Twenty random oligonucleotides (Sigma) were used as a primer for the PCR reaction. Different polymerase chain reaction (PCR) parameters were standardized to optimize the conditions for achieving better results. Finally, PCR was carried out with 50 ng DNA; 200 μM (each) dATP, dCTP, dTTP, and dGTP; 50 pmol oligonucleotides; 0.25 U Taq polymerase; and PCR buffer. The final volume of the reaction mixture was 30 μl. The cycling conditions were 94°C for 2 min, then thirty cycles of denaturation at 94°C for 1 min, thirty cycles of annealing at 42°C for 1 min, and extension at 72°C for 2 min. Final extension was given for 5 min at 72°C. Amplified products (30 μl) were resolved by agarose gel electrophoresis (1%) at 100 V for 1.5 h. The gel was stained with ethidium bromide, visualized under UV light, and photographed.

Antifungal susceptibility testing {#sec2-6}
---------------------------------

### Clinical and laboratory standards institute broth microdilution method {#sec3-1}

Susceptibility of *Candida* isolates to antifungal fluconazole and amphotericin B was done by the broth microdilution method as per the Clinical and Laboratory Standards Institute (CLSI) M27-A3 document using Roswell Park Memorial Institute medium and morpholinepropanesulfonic acid buffer.\[[@ref20]\] The concentration range was tested between 0.125 and 128 μg/ml for fluconazole and 0.016-16 μg/ml for amphotericin B.\[[@ref12]\] Minimum inhibitory concentration (MIC) was recorded as the lowest concentration of the drug that produced a visible decrease in turbidity compared to drug-free growth control according to the CLSI standards. The MIC breakpoints recommended by CLSI guidelines were followed. For fluconazole, MIC breakpoints were as follows: Susceptible, MIC ≤8 μg/ml; susceptible dose-dependent, MIC 16-32 μg/ml; and resistant, MIC ≥64 μg/ml. For amphotericin B, isolates with MICs of ≥1 μg/ml were categorized as resistant.\[[@ref20]\]

### Vitek-2 antifungal susceptibility testing method {#sec3-2}

Inoculum suspensions for Vitek-2 cards were obtained from the overnight cultures, with the turbidity being adjusted to a 1.8-2.2 McFarland standard according to the manufacturer\'s recommendations.\[[@ref12]\] A standardized inoculum suspension was placed into a Vitek-2 cassette along with a sterile polystyrene test tube and an antifungal susceptibility test card for each organism. The loaded cassettes were placed into the Vitek-2 instrument, and the respective inoculum suspensions were diluted appropriately by the instrument, after which the cards were ﬁlled, incubated, and read automatically. The incubation time varied from 9.1 to 27.1 h based on the rate of growth in the drug-free control well.\[[@ref21]\] In accordance with the M27-A3 document, the results from the 48 h reading were used. Complete data (from the CLSI and Vitek-2 methods) for each fungal isolate were recorded.

Statistical analyses {#sec2-7}
--------------------

The reproducibility of AST was assessed by nonparametric correlation coefficient, and AST was considered reproducible if the correlation coefficient was *P* \< 0.05. All statistical analyses were done with the Statistical Package for the Social Sciences (version 17.0; SPSS S.L., Madrid, Spain). All tests of statistical significance were two tailed.

RESULTS {#sec1-3}
=======

With Vitek-2 ID system, 155 of 172 *Candida* isolates including *C. albicans* (*n* = 126), *C. tropicalis* (*n* = 12), *C. krusei* (*n* = 10), *C. glabrata* (*n* = 4), and *C. parapsilosis* (*n* = 3) were correctly identified. Eleven *C. albicans* were misidentified (6.39%) as C. famata (*n* = 6), *C. tropicalis* (*n* = 1), *C. glabrata* (*n* = 1), *C. krusei* (*n* = 1), G. capitatum (*n* = 1), and K. ohmeri (*n* = 1). One each isolate of *C. tropicalis* and *C. parapsilosis* was misidentified as K. ohmeri and C. famata, respectively. Four isolates (2.32%) such as *C. albicans* (*n* = 2), *C. parapsilosis* (*n* = 1), and *C. tropicalis* (*n* = 1) were identified with low discrimination \[[Table 1](#T1){ref-type="table"}\].

###### 

Comparison of Vitek-2 ID system with conventional and molecular methods of identification (*n* = 172)

![](JGID-8-139-g001)

On the other hand by conventional methods, 171 of 172 *Candida* isolates including *C. albicans* 138 (80.23%), *C. tropicalis* 14 (8.14%), *C. krusei* 10 (5.8%), *C. parapsilosis* 5 (2.9%), and *C. glabrata* 4 (2.3%) were correctly identified. Only one *C. albicans* was misidentified as *C. tropicalis*.

All the isolates tested by Vitek-2 ID system and conventional methods were subjected to DNA fingerprinting analysis by using a widely used *C. albicans* specific probe, the CARE-2 probe. Two low discriminated and 11 misidentified isolates by Vitek-2 ID system and one misidentified isolate by conventional methods were identified as *C. albicans* by restriction fragment length polymorphism (RFLP) analysis with CARE-2 probe hybridization \[[Figure 1](#F1){ref-type="fig"}\]. However, NAC isolates did not show any fingerprinting pattern when probed with CARE-2.

![Restriction fragment length polymorphism patterns of Candida isolates, Lanes: M (1 kb ladder), Lane 01--06, 08, 09, and 11--15 are *Candida albicans* isolates and Lane 07, 10, and 16 are nonalbicans isolates (no hybridization or nontypical hybridization with CARE-2 probe)](JGID-8-139-g002){#F1}

The isolates of NAC were subjected to RAPD analysis which produced *Candida* species-specific RAPD patterns distinct for individual ATCC standard strains. All the isolates tested to be NAC by conventional methods (except one *C. albicans* isolate which was misidentified as *C. tropicalis*) exhibited similar results by showing similar typical RAPD patterns to their respective ATCC strains \[[Figure 2](#F2){ref-type="fig"}\]. Misidentified (*n* = 2) and low discriminated isolates (*n* = 2) with Vitek-2 ID system were identified as *C. parapsilosis* (*n* = 2) and *C. tropicalis* (*n* = 2) by RAPD patterns.

![Random amplified polymorphic DNA analysis of *Candida* isolates. Lane M 1 kb ladder; ST1, *Candida parapsilosis* ATCC; ST2, *Candida krusei* ATCC; ST3, *Candida glabrata* ATCC; and ST4, *Candida tropicalis* ATCC; Lane 1--3 are *Candida parapsilosis*; Lane 4--6 are *Candida krusei*; Lane 7--9 are *Candida glabrata*; and 10--12 are *Candida tropicalis*](JGID-8-139-g003){#F2}

Measurement of percentage agreement between the Vitek-2 ID identification system and conventional methods of identification was \>94% for all *Candida* isolates. Measurement of percentage agreement between the Vitek-2 ID system and conventional methods by Kappa was 70% for *C. albicans*, 97.8% for *C. tropicalis*, 97% for *C. krusei*, 96.7% for *C. glabrata*, and 98% for *C. parapsilosis*.

In AST for fluconazole, Vitek-2 AST system showed that 92.4% isolates of the *Candida* species were susceptible. All the isolates of *C. albicans* were susceptible while among NAC, 66.6% isolates were susceptible and remaining 33.4% were resistant. While by the CLSI broth microdilution method, 88.95% of *Candida* species isolates were susceptible with 97.1% *C. albicans* and 54.5% NAC were susceptible for fluconazole. All the isolates of *C. parapsilosis* were found to be susceptible while all the *C. krusei* (100%) were resistant to fluconazole by both the methods \[[Table 2](#T2){ref-type="table"}\]. The measurement of percentage agreement between the Vitek-2 AST system and CLSI broth microdilution method by Kappa was 94% for fluconazole.

###### 

Antifungal susceptibility testing pattern of the *Candida* spp. isolates by the Vitek-2 system and Clinical Laboratory Standards Institute broth microdilution method (*n* = 172)

![](JGID-8-139-g004)

For amphotericin B drug, Vitek-2 AST system showed that 98.3% isolates of *Candida* species were susceptible while 1.7% were resistant. All the isolates of *C. albicans* (100%) and 90.9% of NAC were susceptible \[[Table 2](#T2){ref-type="table"}\]. While when tested by CLSI broth micro-dilution method, 97.7% isolates of *Candida* species were susceptible to amphotericin B. All the isolates of *C. albicans* (100%), *C. tropicalis* (100%), *C. glabrata* (100%), *C. parapsilosis* (100%), and 60% isolates of *C. krusei* were susceptible with remaining 40% isolates of *C. krusei* being resistant. However, using the Vitek-2 AST system, 70% isolates of *C. krusei* were found to be susceptible. Except *C. krusei*, all the other *Candida* species isolates were susceptible to amphotericin B by both methods. The MIC of the two quality control strains was within the range of expected values and showed reproducibility by both methods. For amphotericin B drug susceptibility testing, the measurement of percentage agreement between the Vitek-2 AST system and CLSI broth microdilution method by Kappa was 99%.

The correlation coefficient index (CCI) between Vitek-2 ID system and conventional methods of identification was 0.938, and it was statistically significant (*P* \< 0.05). The CCIs values between the Vitek-2 AST system and the CLSI broth microdilution method for the antifungal agents (fluconazole and amphotericin B) were also highly significant \[[Table 3](#T3){ref-type="table"}\]. Correlation coefficient indices were expressed to a maximum value of 1. All the correlation coefficient indices were statistically significant (*P* \< 0.05).

###### 

Nonparametric correlation coefficient indices between antifungal (fluconazole drug and amphotericin B drug) susceptibility testing by Vitek-2 system and Clinical Laboratory Standards Institute broth microdilution method

![](JGID-8-139-g005)

DISCUSSION {#sec1-4}
==========

*Candida* species is an important cause of systemic mycosis in hospitalized patients, and morbidity and mortality worldwide, especially in critically ill patients.\[[@ref22]\] Among *Candida* species, *C. albicans*, *C. glabrata*, *C. tropicalis*, *C. parapsilosis*, and *C. krusei* were the most common species encountered in routine clinical laboratory samples.\[[@ref23]\] In our study, we have found *C. albicans* (80.8%) as the predominant species followed by *C. tropicalis* (8.13%), *C. krusei* (5.8%), *C. parapsilosis* (2.9%), and *C. glabrata* (2.3%), which is consistent with a previous study of Jha *et al*.,\[[@ref24]\] in which the majority of *Candida* species were *C. albicans* (70%) followed by *C. tropicalis* (13.33%), *C. krusei* (10%), *C. parapsilosis* (3.33%), and C. stellatoidea (3.33%).\[[@ref24]\] A study from South India by Kumari *et al*. in 2014 reported with overall predominance of NAC spp. and the predominant species identified was *C. albicans*.\[[@ref25]\]

In this study, we compared the fully automated Vitek-2 ID system with conventional methods for identification of *Candida* species. Of 172 *Candida* isolates, Vitek-2 identified 155 (90.12%) *Candida* isolates correctly, 13 (7.56%) were misidentified, and 4 (2.32%) were identified with low discrimination. Massonet *et al*.\[[@ref8]\] in their prospective study reported that Vitek-2 identified 41 (67.21%) *Candida* isolates correctly, 10 (16.39%) were not identified, 3 (4.91%) were misidentified, and 7 (11.47%) isolates were identified with low discrimination\[[@ref8]\] whereas other studies reported that Vitek-2 system to correctly identify 98.5%\[[@ref16]\] and 100%\[[@ref26]\] of clinical isolates.

In our study with Vitek-2 ID system, most problems were encountered with the identification of *C. albicans*: 11 isolates were misidentified and two isolates were identified with low discrimination. Graf *et al*.\[[@ref23]\] compared the results of the ID 32C system with Vitek-2 system, out of 241 *Candida* isolates, 222 (92.1%) were unequivocally identified to the species level by the Vitek-2 system, including 11 strains (4.6%) with low discrimination resolved by simple additional tests, 10 (4.1%) of which could not be definitely identified to the species level by additional tests. Four strains (1.7%) were misidentified and five strains (2.1%) could not be identified.\[[@ref23]\]

In this study, the strains were simultaneously tested by the molecular techniques. Molecular techniques are excellent tools for identification and methods are highly reproducible, more discriminatory, high throughput, easy-to-use, digitally portable, and amenable to standardization.\[[@ref27]\] These techniques have been used in a number of studies with *Candida* species.\[[@ref27]\] An advantage of the method described here is the stable and easy-to-read RFLP patterns.\[[@ref28]\] RAPD assay has become one of the most favorable choices for DNA fingerprinting of medically important *Candida* species.\[[@ref29]\]

Baires-Varguez *et al*.\[[@ref30]\] found that RAPD sensitivity for total isolates was 91% (84 of 92 isolates being correctly identified), reinforcing the previously described RAPD procedures for *Candida* species identification.\[[@ref30]\] RAPD fingerprints generated from a single primer correctly identified the species of most (\>98%) of the isolates identified with CHROMagar *Candida* plates as NAC.\[[@ref31]\] However, there were certain limitations in this study; there was no isolate of cryptic species which is very difficult to distinguish with RAPD fingerprints.

In this study, we also evaluated the Vitek-2 AST system with the CLSI broth microdilution method for *Candida* species. A majority of *Candida* isolates were susceptible to both antifungal drugs tested by AST-YS06 Vitek-2 cards and the CLSI M27-A3 method. All the isolates of *C. krusei* (100%) were resistant to fluconazole drug by both the methods also seen by other workers,\[[@ref32]\] emphasizing its intrinsic resistance toward azoles\[[@ref33]\] and poor susceptibility to other antifungals, including amphotericin B.\[[@ref34]\] In current clinical management practices, fluconazole is not recommended as a treatment option for C. Krusei infection\[[@ref35]\] or susceptibility testing.\[[@ref36]\]

The measurement of percentage agreement between the Vitek-2 AST system and CLSI broth microdilution method by Kappa was 94% for fluconazole, quite in concordance with a study by Bourgeois *et al*.,\[[@ref36]\] where the agreements were 94.6%. Earlier in a study, the overall essential agreement between the Vitek-2 AST system and the broth microdilution MICs has been found to range from 97.9% with 24 h broth microdilution result compared to 93.7% with the 48 h bone mineral density result used as reference.\[[@ref21]\] However, we found that for amphotericin B drug susceptibility testing, the measurement of percentage agreement between the Vitek-2 AST system and CLSI broth microdilution method by Kappa was 99%. While the overall essential agreement between the Vitek-2 AST system and the broth microdilution, MICs were found to range from 96.7% (voriconazole) to 99.1% (amphotericin B and flucytosine) with the 24 h broth microdilution result used as the reference in another study.\[[@ref21]\]

The CCIs values between all the methods were statistically significant (*P* \< 0.05). The CCIs values for the Vitek-2 AST system and the CLSI broth microdilution method were also statistically significant. However, the CCIs values for the Vitek-2 AST system were lower than those observed for the CLSI broth microdilution method; this may be because the ranges of antifungal agents in the Vitek-2 AST system do not match exactly with the ranges of the CLSI broth microdilution method.

CONCLUSION {#sec1-5}
==========

The present study revealed that Vitek-2 system reduces the period required for identification and improves the rate of identification of *Candida* species isolates. However, conventional identification methods are still considered reference standard methods, in spite of time-consuming along with ambiguities results, and hence, suited better for research purposes. Therefore, Vitek-2 system appeared to be an alternative method for identification and AST for the *Candida* species to prescribe appropriate antifungal agents for the better management of opportunistic infection among immunosuppressed patients.
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